Broadfin Capital’s Emergent Biosolutions EBS Stock Holding History

Broadfin Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-672,922	Closed	-$26.9M	–	79
2015 Q4	$26.9M	Sell	672,922 -948,910	-59%	-$33.1M	1.66%	15
2015 Q3	$46.2M	Sell	1,621,832 -138,687	-8%	-$4.57M	2.57%	8
2015 Q2	$58M	Sell	1,760,519 -50,000	-3%	-$1.55M	3.12%	8
2015 Q1	$52.1M	Sell	1,810,519 -256,200	-12%	-$7.35M	4.06%	6
2014 Q4	$56.3M	Sell	2,066,719 -13,800	-0.7%	-$329K	4.89%	4
2014 Q3	$44.3M	Hold	2,080,519	–	–	4.65%	5
2014 Q2	$46.7M	Buy	2,080,519 +275,167	+15%	+$6.41M	4.56%	4
2014 Q1	$45.6M	Buy	1,805,352 +731,304	+68%	+$18.5M	4.42%	4
2013 Q4	$24.7M	Sell	1,074,048 -200	-0%	-$4.17K	3.26%	10
2013 Q3	$20.5M	Hold	1,074,248	–	–	3.63%	8
2013 Q2	$15.5M	Buy	+1,074,248	New	+$15.6M	3.03%	13

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Broadfin Capital's EBS Position: Q1 2016 in Review

Broadfin Capital sold out of Emergent Biosolutions (EBS) in Q1 2016, closing a stake of 672,922 shares — an estimated $26.9M sold.

Broadfin Capital first reported a position in EBS in Q2 2013 and held it in 11 quarters. The position peaked at $58M in Q2 2015. 215 funds tracked by Wall St. Rank hold EBS as of Q1 2016.

Broadfin Capital reported no remaining Emergent Biosolutions position as of Q1 2016 after selling out during the quarter.
Broadfin Capital sold 672,922 Emergent Biosolutions shares in Q1 2016, an estimated $26.9M.
Broadfin Capital first reported a position in Emergent Biosolutions in Q2 2013 and held it in 11 quarters.
Broadfin Capital's Emergent Biosolutions position peaked at $58M in Q2 2015.
215 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.